Drug Information

General Information
Drug ID
DR00045
Drug Name
Pravastatin
Synonyms
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; Eptastatin; KS-5015; Oliprevin; Pravachol (TN); Pravastatin (INN); Pravastatin Sodium Salt; Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravastatina; Pravastatina [Spanish]; Pravastatine; Pravastatine [French]; Pravastatinum; Pravastatinum [Latin]; Pravator; Pravator (TN); RMS-431; SQ-31,000; Selektine (TN); Vasten
Drug Type
Small molecular drug
Indication Hypercholesterolemia [ICD11: 5C80.0] Approved [1]
Therapeutic Class
Anticholesteremic Agents
Structure
3D MOL 2D MOL
Formula
C23H36O7
Canonical SMILES
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
InChIKey
TUZYXOIXSAXUGO-PZAWKZKUSA-N
CAS Number
CAS 81093-37-0
Pharmaceutical Properties Molecular Weight 424.5 Topological Polar Surface Area 124
Heavy Atom Count 30 Rotatable Bond Count 11
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 7
XLogP
1.6
PubChem CID
54687
PubChem SID
102979949 , 104234199 , 104305598 , 10852022 , 117544687 , 118048679 , 124899367 , 126665388 , 129317935 , 134337841 , 135014686 , 135610132 , 135650848 , 137002685 , 142742106 , 14758460 , 14880512 , 152034648 , 152164597 , 160963523 , 164814679 , 165235255 , 174007284 , 175266850 , 175426985 , 175612187 , 179148899 , 184545482 , 187072512 , 210279284 , 210281607 , 223554816 , 223682192 , 223745588 , 226393956 , 34718661 , 46504851 , 48416457 , 4962 , 49688762 , 49995722 , 50718915 , 57288813 , 57313644 , 7980374 , 8183732 , 85789083 , 85856288 , 93166931 , 96025096
ChEBI ID
CHEBI:63618
TTD Drug ID
D02RQU
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
BSEP Transporter Info Bile salt export pump Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
OAT3 Transporter Info Organic anion transporter 3 Substrate [5]
OAT4 Transporter Info Organic anion transporter 4 Substrate [6]
OAT7 Transporter Info Organic anion transporter 7 Substrate [7]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [8]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [9]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [10]
P-GP Transporter Info P-glycoprotein 1 Substrate [11]
SLC17A4 Transporter Info Probable small intestine urate exporter Substrate [12]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BSEP Transporter Info Km = 124 microM Human embryonic kidney cells (HEK293)-BSEP [3]
OAT3 Transporter Info Km = 27.2 microM Proximal tubule (S2) cells-OAT3 [6]
OAT4 Transporter Info Km = 257 microM Proximal tubule (S2) cells-OAT4 [6]
OAT7 Transporter Info Km = 1 microM Vector-transfected cells-OAT7 [7]
OATP1B1 Transporter Info Km = 33.7 microM Human embryonic kidney cells (HEK293)-OATP1B1 [13]
OATP1B1 Transporter Info Km = 85.7 microM Human embryonic kidney cells (HEK293)-OATP1B1 [14]
OATP1B1 Transporter Info Km = 57.5 microM Oocytes-OATP1B1 [8]
OATP2B1 Transporter Info Km = 2250 microM Human embryonic kidney cells (HEK293)-OATP2B1 [10]
References
1 Pravastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
4 Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
5 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
6 Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
7 Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. Pharmacogenomics J. 2016 Aug;16(4):341-51.
8 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
9 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
10 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
11 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
12 A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
13 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
14 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.